β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: Are risks related to individual product safety profile?

Derek M. Smith*, Christopher A. Coop, Theodore M. Freeman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: Are risks related to individual product safety profile?'. Together they form a unique fingerprint.

Medicine & Life Sciences